VAXCYTE INC. news, videos and press releases
For more news please use our advanced search feature.
VAXCYTE INC. - More news...
VAXCYTE INC. - More news...
- Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
- Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update
- Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
- Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Vaxcyte Announces Pricing of $1.3 Billion Public Offering
- Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
- Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
- Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
- Vaxcyte Appoints John Furey to Board of Directors
- Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
- Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
- Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
- Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
- Vaxcyte Announces Pricing of $750 Million Public Offering
- Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
- Vaxcyte Appoints Whitney Jones as Chief People Officer
- Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise
- VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
- Vaxcyte Appoints Jacks Lee to Board of Directors
- Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates
- Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
- Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update
- Vaxcyte to Present at Upcoming Investor Conferences
- Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
- Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)
